FT576 results were very underwhelming. anti-BCMA. The number of edits goes up with anticipated improvements in ORR that are not happening in clinics. FATE's iPSC approach led the NK excitement back in late 2020 and it seems iPSC is not delivering. MDACC's cbNK process seems to deliver. Scalability is the question mark.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.